Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Company Overview - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a clinical-stage life sciences company focused on developing therapeutics for the central nervous system that can effectively cross the blood-brain barrier [1] - The company has a pipeline of assets, prominently featuring NEO100, a patented pharmaceutical compound created through proprietary synthesis to ensure pharmaceutical-grade purity and reproducibility [1] Product Development - NeOnc's strategy involves intranasal administration to access the brain via olfactory and trigeminal pathways, providing a non-invasive delivery method aimed at improving patient adherence and enabling more direct drug delivery [1] - Positive Phase 1/2a results for NEO100 were announced in December, with a Phase 2a top-line readout expected in mid-2026 [7] Investment Insights - Stonegate Capital Partners has initiated coverage on NeOnc Technologies, viewing NTHI as a differentiated platform with favorable tolerability and multiple near-term catalysts as the program progresses towards a 2026 readout [1] - The closing and funding of the Quazar Investment is anticipated in the near term, which may provide additional support for the company's initiatives [7]